Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 7/20 | 0.40 |
| ▸ | LOX | P28300 | 4/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | UTRN | P46939 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536253 | 0.82 | HCRTR1 (0.40) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL13164105 | 0.82 | LOXL2 (0.61) | HCRTR1HCRTR2LOXL2LOXLOXL3 | |
| SCHEMBL1437199 | 0.82 | RECQL (0.47) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL30329140 | 0.82 | RECQL (0.47) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL18083206 | 0.82 | NOS3 (0.47) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL10208720 | 0.81 | HCRTR1 (0.38) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| Hydrochloric Acid SCHEMBL25210344 | 0.81 | LOXL2 (0.59) | HCRTR1HCRTR2LOXL2LOXLOXL3 | |
| SCHEMBL17000198 | 0.79 | LOXL2 (0.41) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL28806544 | 0.79 | HCRTR1 (0.38) | HCRTR1HCRTR2LOXL2LOXGRM2 | |
| SCHEMBL31018746 | 0.79 | LOXL2 (0.45) | HCRTR1HCRTR2LOXL2LOXGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3185865-B1 | TETRAHYDRONAPTHTYRIDINE DERIVATIVES AS MGLUR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE. | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10072003-B2 | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. | 2018-09-11 | — | — | US | disclosed |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3185865-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016032921-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-8557992-B2 | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557992-B2 | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-05-09 | — | — | US | disclosed |
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116272-A1 | HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | HCRTR1 68/4885HCRTR2 99/4885LOXL2 4841/4885 |
| US-10072003-B2 | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | GRIN2A, GRIN2C, GRIN2B | HCRTR1 82/4885HCRTR2 37/4885LOXL2 3901/4885 |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | GRIN2A, GRIN2C, GRIN2B | HCRTR1 82/4885HCRTR2 37/4885LOXL2 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.